Yan Ming, Chen Xiaobing, Wang Shuling, Li Yin
Department of Thoracic Surgery , Henan Province Tumor Hospital , Zhengzhou, Henan 450008, China.
Zhongguo Fei Ai Za Zhi. 2008 Feb 20;11(1):126-9. doi: 10.3779/j.issn.1009-3419.2008.01.027.
Epidemiology of lung cancer differs between sexes and it might be partially explained by different sex hormone levels in women and men. There are some epidemiological data indicating that gender is a significant, independent prognostic factor in lung cancer. The aim of this study is to determine expression of ER (estrogen receptor) and AR (androgen receptor) in lung cancer, and evaluate the relationship between their expression and clinical or pathologic characteristics.
Immunohistochemistry assay was used to detect expression of ER and AR.
Positive expression of ER and AR were 14.3%(15/105) and 20%(21/105). Positive expression of ER had no relationship with age, gender, pathology, histological differentiation, TNM staging, size of tumor and lymph node metastasis. Although age, gender, pathology, histological differentiation and size of tumor had no effect on the expression of AR, positive rate of AR in staging III lung cancer was significantly higher than that in staging I lung cancer. The different AR expression was significant between N0 and N2 lymph node metastasis (Chi-Square= 4.7828, P=0.0287).
The expression of ER has no relationship with biological behavior. Positive expression of AR may be correlated with the progression and the lymph node metastasis of lung cancer.
肺癌的流行病学在性别之间存在差异,这可能部分归因于男性和女性不同的性激素水平。有一些流行病学数据表明,性别是肺癌中一个重要的独立预后因素。本研究的目的是确定雌激素受体(ER)和雄激素受体(AR)在肺癌中的表达,并评估它们的表达与临床或病理特征之间的关系。
采用免疫组织化学分析法检测ER和AR的表达。
ER和AR的阳性表达率分别为14.3%(15/105)和20%(21/105)。ER的阳性表达与年龄、性别、病理类型、组织学分化程度、TNM分期、肿瘤大小及淋巴结转移无关。虽然年龄、性别、病理类型、组织学分化程度和肿瘤大小对AR的表达没有影响,但Ⅲ期肺癌中AR的阳性率显著高于Ⅰ期肺癌。在N0和N2淋巴结转移之间,AR的表达差异具有统计学意义(卡方=4.7828,P=0.0287)。
ER的表达与生物学行为无关。AR的阳性表达可能与肺癌的进展及淋巴结转移相关。